“The Open Innovation Program was a resounding success,” says Philippe Lucarelli, Clinical Lead at Gerresheimer. “Of the many exciting ideas and concepts, monti impressed us the most. We look forward to working with the monti team to analyze the solution’s potential in more detail.”
Gerresheimer launched the Open Innovation Program for therapy support at home in July 2023 in partnership with ekipa, an open innovation incubator, with the aim of making sustainable and digital healthcare a reality. The monti team, which has already published the initial findings of its research*, receives EUR 4,000 in prize money as the winner of the program. The next stage will be to validate the research findings in a clinical trial. Over the next few months, Gerresheimer and the monti team will jointly explore the potential of an integrated solution and the possibilities of cooperation.
Gerresheimer — Innovating for a better life
Gerresheimer is working on improving the safety, efficiency, and effectiveness of therapies through innovative containment solutions and liquid drug delivery systems. The Gerresheimer on-body drug delivery device Gx SensAir, for example, is capable of administering large-volume and highly viscous biopharmaceuticals, such as the ones used in chemo- and immunotherapies in cancer treatment.
Drug therapy at home to enhance quality of life
Combining containment solutions and drug delivery systems such as
Gx SensAir with digital technologies and platforms offers the opportunity to closely monitor and support patients, even in their home environment. Depending on the indication, it will be possible in many cases to carry out or continue drug therapy safely at home instead of relying on infusion therapy in hospital. For patients, receiving medical care at home means a significant improvement in their quality of life.
About Gerresheimer
Gerresheimer is the innovative system and solution provider and global partner for the pharma, biotech and cosmetic industry. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, dropper bottles, other bottles and more. Gerresheimer ensures the safe delivery and administration of drugs to the patient. With 36 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for the regional markets. With over 11,000 employees, the company generated revenues of around €1.82bn in 2022. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
Contact Gerresheimer AG
Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264
jutta.lorberg-remove@remove-gerresheimer.com
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 1722424185
marion.stolzenwald-remove@remove-gerresheimer.com
